Blinded Veterans Association Endorses Bosma Enterprises’ Good Works® Ice Melter

February 10, 2021

Blinded Veterans Association is the nation’s only congressionally chartered Veterans Service Organization created for visually impaired veterans.

Blinded Veterans Association organization was established to help veterans and their families meet and overcome the challenges of blindness.

“The Blinded Veterans Association continually strives to better the lives of those who served in the armed forces living with sight loss,” said BVA Executive Director Donald Overton. “Bosma’s mission and sales of its Good Works Ice Melter contribute to that mission. Our endorsement is an extension of BVA’s commitment to sustain a thriving, informed, patriotic and connected community.”

Rooted in more than 100 years of history, Bosma is a nonprofit organizations providing training and employment for people who are blind or visually impaired. Bosma Enterprises is the organization’s business entity. From contract packaging to warehousing, Good Works® products and assembly, Bosma Enterprises helps socially responsible companies with a focus on supplier diversity expand their sourcing options with high-quality goods and services.

Bosma Enterprises’ line of Good Works products, including Ice Melter, are packed and shipped by the organization’s production employees, more than half of whom are blind or visually impaired. Sales of the product create employment for people with vision loss, who would otherwise face a 70% unemployment rate. Revenue supports ongoing programs for people with vision loss as well.

“Good Works Ice Melter is more than a great product,” said Bosma CEO Jeff Mittman. “Each purchase contributes to supporting individuals with vision loss through meaningful employment and comprehensive rehabilitative programs.”

Good Works® Ice Melter is designed to save time, money and the environment. Its blue-colored crystals are more easily seen against ice and snow, preventing overuse. The product, which provides superior melting performance and works at temperatures down to -16°F, is less harmful to concrete, asphalt and landscaping.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version